Status:
COMPLETED
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
55+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate safety parameters of anastrozole with regard to its potential effects on postmenopausal bone loss and on lipid profiles. This trial is conducted to investigate...
Eligibility Criteria
Inclusion
- Women defined as Postmenopausal
- Histologically proven operable invasive breast cancer
- Hormone-receptor-positive breast cancer
Exclusion
- Clinical evidence of metastatic disease
- Bilateral hip fractures or bilateral hip prosthesis
- Receiving or received in last 12 months hormonal therapy for breast cancer, bisphosphonate therapy, oestrogens
- Malabsorption syndrome
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
237 Patients enrolled
Trial Details
Trial ID
NCT00082277
Start Date
April 1 2004
End Date
October 1 2007
Last Update
January 26 2011
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Palm Springs, California, United States
2
Research Site
Jacksonville, Florida, United States
3
Research Site
New Orleans, Louisiana, United States
4
Research Site
New York, New York, United States